NO20052655L - Sammensmeltede heterocykliske forbindelser - Google Patents

Sammensmeltede heterocykliske forbindelser

Info

Publication number
NO20052655L
NO20052655L NO20052655A NO20052655A NO20052655L NO 20052655 L NO20052655 L NO 20052655L NO 20052655 A NO20052655 A NO 20052655A NO 20052655 A NO20052655 A NO 20052655A NO 20052655 L NO20052655 L NO 20052655L
Authority
NO
Norway
Prior art keywords
merged
heterocyclic compounds
treatment
disorders
useful
Prior art date
Application number
NO20052655A
Other languages
English (en)
Other versions
NO20052655D0 (no
Inventor
Juan C Jaen
Xiaoqi Chen
Pingchen Fan
Leping Li
Xi Chen
Jeffrey T Mihalic
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20052655D0 publication Critical patent/NO20052655D0/no
Publication of NO20052655L publication Critical patent/NO20052655L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser, sammensetninger og fremgangsmåter er tilveiebrakt som er anvendelige ved behandling og/eller hindring av en tilstand eller forstyrrelse formidlet av en G- proteinkoblet reseptor. Særlig et forbindelser ifølge oppfinnelsen anvendelige ved behandling og/eUer hindring av spiseforstyrrelser, fedme, angstforstynelser og humørforstyrrelser.
NO20052655A 2002-11-06 2005-06-02 Sammensmeltede heterocykliske forbindelser NO20052655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42445602P 2002-11-06 2002-11-06
PCT/US2003/035543 WO2004043958A1 (en) 2002-11-06 2003-11-06 Fused heterocyclic compounds

Publications (2)

Publication Number Publication Date
NO20052655D0 NO20052655D0 (no) 2005-06-02
NO20052655L true NO20052655L (no) 2005-07-26

Family

ID=32312811

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052655A NO20052655L (no) 2002-11-06 2005-06-02 Sammensmeltede heterocykliske forbindelser

Country Status (16)

Country Link
US (2) US7253179B2 (no)
EP (1) EP1562943A1 (no)
JP (1) JP4547266B2 (no)
KR (1) KR20050103184A (no)
CN (2) CN101134757A (no)
AU (1) AU2003285160B2 (no)
BR (1) BR0316070A (no)
CA (1) CA2505372A1 (no)
EA (1) EA009421B1 (no)
IS (1) IS7833A (no)
MX (1) MXPA05004739A (no)
NO (1) NO20052655L (no)
NZ (1) NZ540328A (no)
PL (1) PL376659A1 (no)
WO (1) WO2004043958A1 (no)
ZA (1) ZA200503654B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
KR20050103184A (ko) 2002-11-06 2005-10-27 암젠 인코포레이션 융합된 헤테로사이클릭 화합물들
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
DE102010025663A1 (de) * 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
BR112013003121A2 (pt) * 2010-08-10 2016-06-28 Abbvie Inc moduladores de trpv3
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
EP2771322A2 (en) 2011-10-24 2014-09-03 AbbVie Inc. Novel trpv3 modulators
CN106588812B (zh) * 2016-12-07 2019-02-22 烟台大学 一种酰氯制备2，4-二取代噻唑啉类化合物的方法
MX2021008426A (es) * 2019-01-14 2021-09-23 Cadila Healthcare Ltd Nuevos derivados de sulfonilurea sustituida.
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US23085A (en) * 1859-03-01 chandler
US199549A (en) * 1878-01-22 Improvement in screw-propellers
US176694A (en) * 1876-04-25 Improvement in screw-cutting die-stocks
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
EP0257701A1 (en) 1986-08-15 1988-03-02 Cedona Pharmaceuticals B.V. A process for preparing hydroxyl derivatives of compounds containing a carbazole, dibenzofurane or dibenzothiophene group
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
CA2112744A1 (en) 1991-07-05 1993-01-21 Vittorrio Vecchietti Hydroisoquinoline derivatives
DE69332945T2 (de) 1992-09-29 2004-05-19 Toray Industries, Inc. Indol-derivat, verfahren zu dessen herstellung und dessen medizinische anwendung
US5272146A (en) 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
JP4110579B2 (ja) 1997-01-16 2008-07-02 東レ株式会社 インドロモルヒナン誘導体および脳障害治療・予防剤
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
JP2001525178A (ja) 1997-12-03 2001-12-11 スミスクライン ビーチャム コーポレーション ヒト１１ｃｂスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU6035999A (en) 1998-09-17 2000-04-03 Incyte Pharmaceuticals, Inc. Human gpcr proteins
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
AU1802000A (en) 1998-12-28 2000-07-24 Takeda Chemical Industries Ltd. Screening method
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
CA2371821A1 (en) 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2000070347A1 (en) 1999-05-19 2000-11-23 Astrazeneca Ab Assays for agonists, agonists and inverse agonists of melanin concentrating hormone (mch) binding to the somatostatin-like receptor (slc-1)
AU5869100A (en) 1999-06-08 2000-12-28 Regents Of The University Of California, The Melanin concentrating hormone receptor
WO2001005947A1 (en) 1999-07-14 2001-01-25 Merck & Co., Inc. Melanin-concentrating hormone receptor
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
WO2001036479A1 (en) 1999-11-16 2001-05-25 Merck & Co., Inc. G-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
JP2003532388A (ja) 2000-03-15 2003-11-05 メルク エンド カムパニー インコーポレーテッド メラニン凝集ホルモン受容体キメラおよび融合タンパク質
JP2005229804A (ja) 2000-03-24 2005-09-02 Astellas Pharma Inc 新規なメラニンコンセントレーティングホルモン受容体
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
JP2004502423A (ja) 2000-07-05 2004-01-29 シナプティック・ファーマスーティカル・コーポレーション ヒトメラニン濃縮ホルモン受容体（ｍｃｈ１）をコードするｄｎａ及びその使用
AU783403B2 (en) 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
WO2002003070A1 (fr) 2000-07-05 2002-01-10 Takeda Chemical Industries, Ltd. Procede de criblage d'antagoniste/agoniste du recepteur de l'hormone de concentration de la melanine (mch)
WO2002004433A2 (en) * 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
EA200300305A1 (ru) 2000-10-20 2003-08-28 Пфайзер Продактс Инк. Альфа-арилэтаноламины и их применение в качестве агонистов бета-адренергических рецепторов
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
DE60112791T2 (de) * 2000-12-22 2006-06-08 Schering Corp. Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
HUP0400252A3 (en) 2001-03-21 2011-09-28 Pharmacopeia Drug Discovery Aryl and biaryl compounds having mch modulatory activity, pharmaceutical compositions containing them and process for producing them
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
ATE460163T1 (de) 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
WO2002089729A2 (en) * 2001-05-04 2002-11-14 Tularik Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
WO2002094799A2 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
CN1592739A (zh) * 2001-11-26 2005-03-09 先灵公司 用于治疗肥胖和cns疾病的基于哌啶的mch拮抗剂
EP1465635A4 (en) 2002-01-10 2005-04-13 Neurogen Corp MELANIN-CONCENTRATING HORMONIC RECEPTOR LIGANDS: SUBSTITUTED 2- (4-BENZYL-PIPERAZIN-1-YLMETHYL) AND 2- (4-BENZYL-DIAZEPAN-1-YLMETHYL) -1H-BENZOIMIDAZOLE ANALOGUES
KR20050103184A (ko) 2002-11-06 2005-10-27 암젠 인코포레이션 융합된 헤테로사이클릭 화합물들

Also Published As

Publication number Publication date
NO20052655D0 (no) 2005-06-02
US20080058365A1 (en) 2008-03-06
KR20050103184A (ko) 2005-10-27
PL376659A1 (pl) 2006-01-09
EP1562943A1 (en) 2005-08-17
EA009421B1 (ru) 2007-12-28
US20040147538A1 (en) 2004-07-29
ZA200503654B (en) 2006-09-27
CN1735613A (zh) 2006-02-15
AU2003285160A1 (en) 2004-06-03
NZ540328A (en) 2008-02-29
JP2006508130A (ja) 2006-03-09
WO2004043958A1 (en) 2004-05-27
AU2003285160B2 (en) 2009-06-04
IS7833A (is) 2005-05-02
JP4547266B2 (ja) 2010-09-22
EA200500770A1 (ru) 2005-12-29
CA2505372A1 (en) 2004-05-27
MXPA05004739A (es) 2005-08-02
CN1330651C (zh) 2007-08-08
US7253179B2 (en) 2007-08-07
CN101134757A (zh) 2008-03-05
BR0316070A (pt) 2005-09-27

Similar Documents

Publication Publication Date Title
NO20052655L (no) Sammensmeltede heterocykliske forbindelser
LTPA2021516I1 (no)
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
WO2002089729A3 (en) Fused heterocyclic compounds
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
NO20055837L (no) Immunsupprimerende forbindelser og sammensetninger
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
ME01530B (me) Polimorfni oblici 3- (4-amino-1- okso-1, 3-dihidro- izoindol -2-il)-piperidin-2,6- diona
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
WO2005046603A3 (en) Pyridine compounds
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
ATE401877T1 (de) Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen
DK1580188T3 (da) Forbindelser af arylurea som kinaseinhibitorer
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
NO20091052L (no) Diaryleterderivater og anvendelser derav
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
NO20073369L (no) Modulatorer av muskarinreseptorer
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application